Company Launches New Rapid Pathogen Identification Test for Bloodstream Infections
Bacterial species can be identified in 20 minutes (Sept. 10)
On September 10, AdvanDx, Inc., based in Woburn, Mass., announced the commercial launch of QuickFISH, a new rapid pathogen identification test for potential life-threatening bloodstream infections.
The test will be available on September 24.
QuickFISH is designed to help clinicians, hospital pharmacists, and clinical microbiologists to optimize antibiotic therapy much earlier for patients with bloodstream infections, including septicemia, caused by bacterial pathogens, including Staphylococcus aureus and coagulase-negative staphylococci.
AdvanDx received 510(k) clearance from the FDA on April 3, 2012. Additional QuickFISH assays for identification of other clinically important microbial species are currently in development for launch in 2012 and 2013.
The QuickFISH diagnostic platform allows 20-minute species identification of bacteria directly from positive blood cultures. Pathogen identification can be reported at the same time as the reporting of gram-stain results.
For more information, visit the AdvanDx, Inc. Web site.